The estimated Net Worth of Partners Ii Incalta Biophar... is at least $7.82 millió dollars as of 7 May 2004. Partners Biophar owns over 3,100 units of Rigel Pharmaceuticals stock worth over $104,409 and over the last 21 years Partners sold RIGL stock worth over $7,720,105.
Partners has made over 11 trades of the Rigel Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Partners sold 3,100 units of RIGL stock worth $66,650 on 7 May 2004.
The largest trade Partners's ever made was selling 111,696 units of Rigel Pharmaceuticals stock on 19 February 2004 worth over $2,233,920. On average, Partners trades about 33,698 units every 7 days since 2004. As of 7 May 2004 Partners still owns at least 8,050 units of Rigel Pharmaceuticals stock.
You can see the complete history of Partners Biophar stock trades at the bottom of the page.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke és Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: